Clinical IntelligencePatient Context and What Changed

What changed since you last looked.

New letters, results, medication changes and monitoring enter the record; Reedley lays out what is new since a chosen point, each line linked; you decide what matters.

In the development build · synthetic data

At the previous review · 14 Nov 2025

  • Amlodipine 5 mg once daily
  • Ramipril 10 mg once daily
  • Atorvastatin 20 mg at night

Now · 12 Nov 2026 10:25

  • Lercanidipine 10 mg once dailyNew since review
  • Ramipril 10 mg once daily
  • Atorvastatin 20 mg at night
  • Dapagliflozin 10 mg once dailyNew since review

Synthetic patient Illustrative demonstration · intended workflow 44 new entries since 14 Nov 2025 · 18 are shown in this demonstration, each with its source · simulated clinical system

Interactive demonstration

Synthetic patient · pause, step and replay at any point

Patient Context and What Changed

Synthetic patient

What is new since a chosen point, grouped and dated, each line linked to its source.

Daniel OKONKWONHS 999 000 0115Born 02 Nov 1961 · 65 y · MaleAs of 12 Nov 2026 10:25 · before the medication review
Daniel OKONKWO NHS 999 000 0115

Born 02 Nov 1961 · 65 y · Male · As of 12 Nov 2026 10:25 · before the medication review

What is new since a chosen point, grouped and dated, each line linked to its source.

Step 1 of 7 · Previous review found

  1. Previous review found
  2. Record then and now Illustrative
  3. New correspondence
  4. Medication changes
  5. New investigations
  6. New monitoring obligations Illustrative
  7. Still open

Since the previous medication review · 14 Nov 2025 · K. AHMED

Allergies and intolerances: Codeine — nausea and vomiting (intolerance)

14 Nov 2025 · previous review12 Nov 2026 · now

Previous review found in the record

Structured medication review

Structured medication review. Taking amlodipine 5 mg, ramipril 10 mg and atorvastatin 20 mg as prescribed. Home BP average 146/88. No side effects reported. Next medication review 14 Nov 2026.

“Since the previous review” is taken here from a dated review entry. In the development build, “since my last review” comes from Reedley’s own record of activity and simulated encounters.

44 new entries since 14 Nov 2025

  • 1 problem
  • 4 medication events
  • 7 consultations
  • 4 results
  • 1 referral
  • 11 letter paragraphs
  • 16 work events

44 new entries since 14 Nov 2025 · 18 are shown in this demonstration, each with its source · simulated clinical system

The record then and now · what is new since the previous review is marked

At the previous review · 14 Nov 2025

Medicines

  • Amlodipine 5 mg once dailyChanged since
  • Ramipril 10 mg once daily
  • Atorvastatin 20 mg at night

Problems

  • Essential hypertension
  • Hypercholesterolaemia
  • Chronic kidney disease stage 3a

Latest results, as reported

  • U&E · eGFR 59 · no laboratory flag (14 Nov 2025)Changed since
  • Urine ACR 31 mg/mmol · flagged H by the laboratory (14 Nov 2025)Changed since

Monitoring · draft rules

  • Ramipril · U&E at least every 12 months (draft rule)

Open work

  • No open Reedley work items for this patient on 14 Nov 2025.

Now · 12 Nov 2026 10:25

Medicines

  • Lercanidipine 10 mg once dailyNew since 14 Nov 2025
  • Ramipril 10 mg once daily
  • Atorvastatin 20 mg at night
  • Dapagliflozin 10 mg once dailyNew since 14 Nov 2025

Problems

  • Essential hypertension
  • Hypercholesterolaemia
  • Chronic kidney disease stage 3a
  • PalpitationsNew since 14 Nov 2025

Latest results, as reported

  • U&E · eGFR 52 · no laboratory flag (9 Nov 2026)New since 14 Nov 2025
  • Urine ACR 38 mg/mmol · flagged H by the laboratory (3 Jun 2026)New since 14 Nov 2025

Monitoring · draft rules

  • Ramipril · U&E at least every 12 months (draft rule)
  • Dapagliflozin · U&E at least every 12 months (draft rule)New since 14 Nov 2025

Open work

  • Blood pressure recheck · actioned · booked 16 Nov, attendance not yet confirmedNew since 14 Nov 2025
  • Structured medication review · assignedNew since 14 Nov 2025

Then: Consultation · 14 Nov 2025 · K. AHMED; Result · received 14 Nov 2025 16:05. Now: medication record · as at 12 Nov 2026; Result · received 9 Nov 2026 15:20; Result · received 3 Jun 2026 15:48.

New correspondence 3

  1. 2 Sep 2026Cardiology clinic letter (Dr J. MORLEY) · received 2 Sep 2026 · no further cardiology follow-up arrangedCardiology clinic letter ¶3 · dated 2 Sep 2026
  2. 5 Oct 2026Renal clinic letter (Dr A. FENWICK) · received 5 Oct 2026 · names amlodipine, which the record shows stoppedDiffers from the medication recordRenal clinic letter ¶2 · dated 5 Oct 2026
  3. 20 Oct 2026Renal clinic reply · dated 20 Oct, received 23 Oct 2026 · refers to lercanidipineLater correspondence addresses itRenal clinic reply ¶1 · dated 20 Oct 2026

Sources · each entry opens here

Dr J. MORLEY

I would recommend continuing his current antihypertensive treatment, aiming for a clinic blood pressure below 140/90 mmHg.

Dr A. FENWICK

Please increase amlodipine to 10 mg once daily and recheck blood pressure in 4 weeks.

Dr A. FENWICK

Thank you for your query of 6 October. My letter of 5 October was written from an out-of-date medication list and should have referred to lercanidipine. Please continue lercanidipine 10 mg once daily; I am not asking for any change to it.

Medication changes 4

  1. 22 Apr 2026Amlodipine 5 mg → 10 mg once dailyMedication record · 22 Apr 2026
  2. 17 Jun 2026Amlodipine stopped · reason recorded: ankle oedemaMedication record · 17 Jun 2026
  3. 17 Jun 2026Lercanidipine 10 mg once daily startedMedication record · 17 Jun 2026
  4. 7 Oct 2026Dapagliflozin 10 mg once daily started · asked for in the renal clinic letterMedication record · 7 Oct 2026

Sources · each entry opens here

Dr S. PATEL

Amlodipine increased from 5 mg to 10 mg once daily.

Dr S. PATEL

Amlodipine stopped. Reason recorded: ankle oedema.

Dr S. PATEL

Lercanidipine 10 mg once daily started. Indication: hypertension.

K. AHMED

Dapagliflozin 10 mg once daily started. No indication text entered.

New investigations, as reported 4

Shown as the laboratory reported them. Reedley does not interpret results or the change between them.

  1. 3 Jun 2026U&E · creatinine 124 µmol/L, eGFR 56 · no laboratory flagResult · received 3 Jun 2026 15:48
  2. 3 Jun 2026Urine ACR 38 mg/mmol · flagged H by the laboratoryResult · received 3 Jun 2026 15:48
  3. 1 Jul 2026ECG · sinus rhythm, rate 72 per minuteResult · 1 Jul 2026
  4. 9 Nov 2026U&E · creatinine 131 µmol/L, eGFR 52 · no laboratory flag · review recorded 12 Nov 08:31Result · received 9 Nov 2026 15:20

Sources · each entry opens here

U&E: Na 140 mmol/L, K 4.7 mmol/L, creatinine 124 µmol/L, eGFR 56 mL/min/1.73m² · no laboratory flag

Urine albumin:creatinine ratio 38 mg/mmol · flagged H by the laboratory

12-lead ECG: sinus rhythm, rate 72 per minute (practice-recorded report)

U&E: Na 140 mmol/L, K 4.6 mmol/L, creatinine 131 µmol/L, eGFR 52 mL/min/1.73m² · no laboratory flag

New monitoring obligations · draft rules 2

Practice draft rules · draft · unsigned · no named clinical owner yet. The draft rules do not yet take account of kidney function category, age or indication; a clinician sets each patient’s interval.

  1. 7 Oct 2026Dapagliflozin · U&E at least every 12 months (draft rule) · next due by 9 Nov 2027Practice monitoring rule · draft · unsigned: “U&E at least every 12 months while on dapagliflozin”Medication record · 7 Oct 2026
  2. 7 Oct 2026U&E 4 to 6 weeks after starting dapagliflozin (renal clinic letter) · received 9 Nov · review recorded 12 NovClosedRenal clinic letter ¶3 · dated 5 Oct 2026Reedley work history · 12 Nov 2026 08:31

Sources · each entry opens here

K. AHMED

Dapagliflozin 10 mg once daily started. No indication text entered.

Dr A. FENWICK

His urine albumin:creatinine ratio remains raised. I would be grateful if you could start dapagliflozin 10 mg once daily for his chronic kidney disease and check his urea and electrolytes 4 to 6 weeks after starting.

Reedley, from the clinical record (Simulated)

Reviewed and filed by K. AHMED 12 Nov 2026 08:31. U&E item closed · completed.

Unresolved at this review 3

  1. 26 Oct 2026Blood pressure recheck · actioned · booked 16 Nov 09:20 · attendance not yet confirmedActionedReedley work history · 29 Oct 2026 14:06Renal clinic reply ¶2 · dated 20 Oct 2026
  2. 7 Oct 2026Dapagliflozin has no indication recorded on the medication entryUnresolvedmedication record · as at 12 Nov 2026
  3. 2 Nov 2026Structured medication review · assigned · this appointmentAssignedReedley work history · 2 Nov 2026 08:15

Sources · each entry opens here

Reedley (Simulated)

Booked by the patient for 16 Nov 09:20 · attendance not yet confirmed.

Dr A. FENWICK

I would still be grateful if his blood pressure could be rechecked in 4 weeks, as planned.

Dapagliflozin 10mg tablets 10 mg once daily · no indication recorded · last issued 2 Nov 2026

K. AHMED

Assigned: structured medication review · owner K. AHMED · appointment 12 Nov 10:30 (medication review date on the repeat template: 14 Nov 2026).

Other new entries 2

  1. 1 Jul 2026Problem added: palpitationsProblem list · recorded 1 Jul 2026
  2. 1 Jul 2026Referral to cardiology outpatients (routine)Referral · 1 Jul 2026

Sources · each entry opens here

Palpitations

Referral to cardiology outpatients (routine): intermittent palpitations.

Runs against a simulated clinical system; the clinical record remains the source of truth.

In the development build · synthetic data, except steps marked Illustrative · Scripted reconstruction: the development build itself is not running on this page.

  • Changes grouped by date and source, since your last review or a set window.
  • Overviews shaped for the task: medication review, acute or diabetes review.
  • Every line opens to its source; the snapshot time is always shown.

From what arrives to what you decide

  1. What entersNew letters, results, medication changes and monitoring
  2. What Reedley preparesWhat is new since a chosen point, each line linked to its source
  3. What the clinician decidesYou decide what matters

What it does not do · what exists today

  • Reedley does not decide what is clinically significant; it lays out what is new.
  • “Last review” is taken from Reedley’s own record of activity in the development build.
  • Episodes Reedley derives from the record are labelled as Reedley-derived.

Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance

See it with your own work in mind.

Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.